Research Updates

“I became interested in glaucoma because I liked the long-term aspect of it. It is through that long-term relationship that we can really get to know our patients and help them.” — Carla Siegfried, MD

Study indicates treatment using insulin may restore vision in glaucoma patients.

Glaucoma Research Foundation Shaffer Grants present a unique opportunity for investigators to pursue innovative ideas in the spirit of high risk/high reward scientific discovery.

ARVO is the annual meeting of the Association for Research in Vision and Ophthalmology.

James D. Brandt, MD co-moderated the session “New Horizons in Glaucoma Drug Delivery” with Anne L. Coleman, MD, PhD at the 7th annual Glaucoma 360 New Horizons Forum in San Francisco.

Biomarkers can provide physicians with better tools to diagnose and manage glaucoma before vision is lost, as well as accelerate better treatments for glaucoma.

We talked with Dr. Janey Wiggs, a scientific advisor for Glaucoma Research Foundation, at the AAO 2017 meeting in New Orleans about what’s new in genetic research for treating glaucoma.

Andrew Huberman, PhD is a principal investigator in the Catalyst for a Cure Biomarkers Team funded by Glaucoma Research Foundation in San Francisco, CA.

The Srinivasan Laboratory at the University of California, Davis, develops novel optical imaging techniques and diagnostics with applications spanning from basic to clinical research.

Dr. Goldberg’s glaucoma research is directed at neuroprotection and regeneration of retinal ganglion cells and other retinal neurons.

Retinal ganglion cells (RGCs) are particularly important in glaucoma because they are the cells that are damaged by the disease.

“We’re not just trying to achieve some answer in terms of scientific curiosity, but our aim is to really help people who are suffering from this disease.” — Alfredo Dubra, PhD

Vision scientists have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma.

Researchers like Dr. Andrew Huberman and the other Catalyst for a Cure scientists are focused on stopping blindness from glaucoma.

Dr. John Flanagan is actively working on research to discover new ways to treat glaucoma.

Glaucoma Research Foundation (GRF) is dedicated to supporting promising research conducted by dedicated scientists.

If you’re looking for a medical research charity to support, you probably want to know with confidence that your donation is going to make an impact and help people.

Evidence is building that nanoparticles will prove an excellent drug delivery system, and it won’t be long until this technology reaches patients.

By using a new contact lens technology, researchers are hoping to gain new insight into obstructive sleep apnea by continuously monitoring the eye pressure even during sleep cycles.

Recently, the National Eye Institute released an optimistic report stating that exosomes secreted by stem cells are protective to the retina.

Through the Shaffer Grants, Glaucoma Research Foundation invests in a wide variety of projects that increase scientific understanding of glaucoma.

Since oxidative stress is associated with damage to the optic nerve in glaucoma, you may wonder whether you should be increasing the antioxidants in your diet.

Connecting pieces of information by finding a common thread often takes glaucoma researchers in unexpected directions.

Using an insert, it should be possible to deliver a consistent dose of medication to the eye while reducing the initial sting or burn, with less of the medication lost to the tear duct or sinuses.

“Two clinical trials are underway for vision restoration,” says Dr. Huberman. “These trials would not be possible without the identification of new biomarkers.”